Scholarlink

<p>This study aims to design and synthesize novel benzothiazole based thiazolidinone derivatives as potential inhibitors of carbohydrate-hydrolyzing enzymes, addressing the urgent need for effective therapeutic agents to manage type 2 diabetes mellitus through enzymatic regulation. All the novel benzothiazole based thiazolidinone derivatives were investigated against α-amylase and α-glucosidase with significant potential for treating a common metabolic problem, diabetes mellitus. The synthesis of these derivatives was confirmed using <sup>1</sup>HNMR, <sup>13</sup>CNMR, and HREI-MS. Biological assessment was carried out by comparing the new analogs with acarbose (IC<sub>50</sub> = 5.40 ± 0.30&#xa0;µM for α-amylase and 5.70 ± 0.50&#xa0;µM for α-glucosidase). The synthesized analogs exhibited a range of inhibitory activities with IC<sub>50</sub> values for α-amylase ranging from 19.30 ± 0.20&#xa0;µM to 3.60 ± 0.10&#xa0;µM and for α-glucosidase ranged from 20.60 ± 0.40 to 4.40 ± 0.20&#xa0;µM. Notably, compound 9 with a trifluoromethyl group showed significant binding interaction, contributing to its high potency. Molecular docking studies provided insights into the binding interactions of all the potent analogs, while density functional theory (DFT) calculations explored the stability and reactivity of the active compounds. Additionally, ADMET analysis was conducted for examining drug-likeness of the potent compounds.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, SAR, and computational evaluation of novel thiazolidinone-based antidiabetic hybrids: insights from enzyme kinetics and DFT studies

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Abdul Hafeez,
  • Shoaib Khan,
  • Tayyiaba Iqbal,
  • Eman Alzahrani,
  • Faez Falah Alshehri,
  • Zafer Saad Al Shehri,
  • Sobhi M. Gomha,
  • Magdi E. A. Zaki

摘要

This study aims to design and synthesize novel benzothiazole based thiazolidinone derivatives as potential inhibitors of carbohydrate-hydrolyzing enzymes, addressing the urgent need for effective therapeutic agents to manage type 2 diabetes mellitus through enzymatic regulation. All the novel benzothiazole based thiazolidinone derivatives were investigated against α-amylase and α-glucosidase with significant potential for treating a common metabolic problem, diabetes mellitus. The synthesis of these derivatives was confirmed using 1HNMR, 13CNMR, and HREI-MS. Biological assessment was carried out by comparing the new analogs with acarbose (IC50 = 5.40 ± 0.30 µM for α-amylase and 5.70 ± 0.50 µM for α-glucosidase). The synthesized analogs exhibited a range of inhibitory activities with IC50 values for α-amylase ranging from 19.30 ± 0.20 µM to 3.60 ± 0.10 µM and for α-glucosidase ranged from 20.60 ± 0.40 to 4.40 ± 0.20 µM. Notably, compound 9 with a trifluoromethyl group showed significant binding interaction, contributing to its high potency. Molecular docking studies provided insights into the binding interactions of all the potent analogs, while density functional theory (DFT) calculations explored the stability and reactivity of the active compounds. Additionally, ADMET analysis was conducted for examining drug-likeness of the potent compounds.